Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. resumes supply of Lilly's COVID-19 antibody combo to some states

08/27/2021 | 06:50pm EDT

Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.

The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.

With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/resumption-in-distribution-bamlanivimabetesevimab.aspx.

Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.

The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.

The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.

Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.

Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 0.73% 1421 Delayed Quote.5.13%
REGENERON PHARMACEUTICALS 1.18% 569.37 Delayed Quote.17.86%
VIR BIOTECHNOLOGY, INC. 0.50% 39.93 Delayed Quote.49.10%
All news about REGENERON PHARMACEUTICALS
04:50aSANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
04:24aREGENERON, SANOFI : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
DJ
01:50aSANOFI : Regeneron's Dupixent Cuts Itch in Late-Stage Skin Disease Study
MT
10/21REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
10/20SANOFI : Regeneron Win Expanded US FDA Nod for Asthma Drug Dupixent
MT
10/20REGENERON PHARMACEUTICALS : Sanofi Say FDA Has Expanded Approval of Dupixent to Include Ch..
MT
10/20REGENERON PHARMACEUTICALS : FDA Expands Approval of Dupixent® (dupilumab) to Include Child..
PR
10/14REGENERON PHARMACEUTICALS : FDA Accepts Regeneron's 'Regen-Cov" For Priority Review for Tr..
MT
10/14Health Care Stocks Climb Pre-Bell Thursday
MT
10/14REGENERON PHARMACEUTICALS : US FDA Accepts Regeneron's Regen-Cov For Priority Review for C..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 14 402 M - -
Net income 2021 7 227 M - -
Net Debt 2021 - - -
P/E ratio 2021 8,60x
Yield 2021 -
Capitalization 59 196 M 59 196 M -
Capi. / Sales 2021 4,11x
Capi. / Sales 2022 4,85x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 569,37 $
Average target price 681,64 $
Spread / Average Target 19,7%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS17.86%59 196
GILEAD SCIENCES, INC.14.98%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.25.77%65 142
VERTEX PHARMACEUTICALS-20.84%48 536
BEIGENE, LTD.45.24%35 024